GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aridis Pharmaceuticals Inc (OTCPK:ARDS) » Definitions » Effective Interest Rate on Debt %

Aridis Pharmaceuticals (Aridis Pharmaceuticals) Effective Interest Rate on Debt % : 0.00% (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Aridis Pharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Aridis Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Sep. 2023 was $0.00 Mil. Aridis Pharmaceuticals's average total debt for the quarter that ended in Sep. 2023 was $5.57 Mil. Therefore, Aridis Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2023 was 0.00%.


Aridis Pharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for Aridis Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aridis Pharmaceuticals Effective Interest Rate on Debt % Chart

Aridis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Effective Interest Rate on Debt %
Get a 7-Day Free Trial - - - 7.32 2.00

Aridis Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 - - - -

Competitive Comparison of Aridis Pharmaceuticals's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Aridis Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aridis Pharmaceuticals's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Aridis Pharmaceuticals's Effective Interest Rate on Debt % falls into.



Aridis Pharmaceuticals Effective Interest Rate on Debt % Calculation

Aridis Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2022 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2021 )+Total Debt  (A: Dec. 2022 ))/ count )
=-1  *  -0.121/( (5.978+6.13)/ 2 )
=-1  *  -0.121/6.054
=2.00 %

where

Total Debt  (A: Dec. 2021 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=5.282 + 0.696
=5.978

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1.292 + 4.838
=6.13

Aridis Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2023 )+Total Debt  (Q: Sep. 2023 ))/ count )
=-1  *  0/( (6.295+4.84)/ 2 )
=-1  *  0/5.5675
=0.00 %

where

Total Debt  (Q: Jun. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1.002 + 5.293
=6.295

Total Debt  (Q: Sep. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.854 + 3.986
=4.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Sep. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Aridis Pharmaceuticals  (OTCPK:ARDS) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Aridis Pharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aridis Pharmaceuticals (Aridis Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
983 University Avenue, Building B, Los Gatos, CA, USA, 95032
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
Executives
Fibrosis Foundation Cystic 10 percent owner 4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814
Hasan Jafri officer: Chief Medical Officer 5941 OPTICAL COURT, SAN JOSE CA 95138
Vu Truong director, 10 percent owner, officer: CEO, CSO, Director 5941 OPTICAL CT., SAN JOSE CA 95138
Eric Patzer director, 10 percent owner 5941 OPTICAL CT., SAN JOSE CA 95138
John F Hamilton director 1360 O'BRIEN DR, MENLO PARK CA 94025
Michael Adrian Nazak officer: Chief Financial Officer 5941 OPTICAL COURT, SAN JOSE CA 95138
Susan Richards Windham-bannister director 78 BLANCHARD ROAD, BURLINGTON MA 01803
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Fred Kurland officer: Chief Financial Officer C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Wolfgang Dummer officer: Chief Medical Officer 5491 OPTICAL CT., SAN JOSE CA 95138
Robert R Ruffolo director
Shawn Lu director C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326
Robert K. Coughlin director 5941 OPTICAL CT., SAN JOSE CA 95138
Craig S Gibbs director C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025

Aridis Pharmaceuticals (Aridis Pharmaceuticals) Headlines